- Catalogue N°
- 853.080.000 - 200µg / 200µl
853.080.005 - 500µg / 500µl
- Target species
- Recognises the TRAIL, APO2L antigen, a 32 kDa protein
- Flow Cytometry
- Functional assay
- Myeloma X63/AG.8653 x Balb/c spleen cells
- Recombinant human TRAIL
- 200µg or 500µg (Discovery Size also available please enquire)
- Mouse IgG1 Kappa light chain
- Phosphate-buffered saline. Sterile-filtered through 0.22 μm and treated to remove endotoxins. Carrier and preservative free
- Stable at +2-8°C for 12 months. For longer storage freeze aliquots.
- Biological Activity
- Enhances TRAIL induced apoptosis
TRAIL, TNF-Related Apoptosis-Inducing Ligand (TRAIL), is a member of the tumor necrosis factor (TNF) family, also designated as Apo-2 ligand (Apo-2L) and CD253. TRAIL is a 281-amino acid protein, related most closely to Fas/Apo-1 ligand. It is expressed at cell surface as a transmembrane protein with an extracellular region and a homotrimeric subunit structure and also exists as a soluble form.
TRAIL interacts with several receptors: two pro-apoptotic death receptors DR4 (TRAIL R1) and DR5 (TRAIL R2) and three anti-apoptotic decoy receptors DcR1 (TRAIL R3), DcR2 (TRAIL R4) and osteoprotegrin (OPG). Soluble TRAIL induces apoptosis through these death receptors in many transformed cells (lymphoid as well as non-lymphoid tumor cell lines).
Because of its role in apoptosis and its stable trimer, TRAIL was described as a potential tumor-specific cancer therapeutic.
Version 9 - 06.19
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.